Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Summary

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Ganglioneuroblastoma
• Ganglioneuroblastoma, Nodular
• Neuroblastoma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

365 days to 30 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Children's Oncology Group

Last updated on ClinicalTrials.gov

August 25, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites